HRP20251668T1 - 2-(2,6-dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-dion za uporabu u liječenju ne-hodgkinova limfoma - Google Patents

2-(2,6-dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-dion za uporabu u liječenju ne-hodgkinova limfoma

Info

Publication number
HRP20251668T1
HRP20251668T1 HRP20251668TT HRP20251668T HRP20251668T1 HR P20251668 T1 HRP20251668 T1 HR P20251668T1 HR P20251668T T HRP20251668T T HR P20251668TT HR P20251668 T HRP20251668 T HR P20251668T HR P20251668 T1 HRP20251668 T1 HR P20251668T1
Authority
HR
Croatia
Prior art keywords
morpholinoazetidin
dioxopiperidin
isoindoline
hodgkin
dione
Prior art date
Application number
HRP20251668TT
Other languages
English (en)
Croatian (hr)
Inventor
Anton Maria Soraya Carrancio
Tonia J. Buchholz
Antonia Lopez-Girona
Rama Krishna Narla
Michael POURDEHNAD
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of HRP20251668T1 publication Critical patent/HRP20251668T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20251668TT 2019-04-12 2020-04-09 2-(2,6-dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-dion za uporabu u liječenju ne-hodgkinova limfoma HRP20251668T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962833432P 2019-04-12 2019-04-12
EP20722180.5A EP3952880B1 (en) 2019-04-12 2020-04-09 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione for use in the treatment of non-hodgkin lymphoma
PCT/US2020/027358 WO2020210418A1 (en) 2019-04-12 2020-04-09 Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Publications (1)

Publication Number Publication Date
HRP20251668T1 true HRP20251668T1 (hr) 2026-02-27

Family

ID=70465546

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251668TT HRP20251668T1 (hr) 2019-04-12 2020-04-09 2-(2,6-dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-dion za uporabu u liječenju ne-hodgkinova limfoma

Country Status (27)

Country Link
US (3) US11390617B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952880B1 (cg-RX-API-DMAC7.html)
JP (1) JP7562557B2 (cg-RX-API-DMAC7.html)
KR (1) KR102944213B1 (cg-RX-API-DMAC7.html)
CN (1) CN114144182B (cg-RX-API-DMAC7.html)
AR (1) AR119715A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020270917B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020372A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132538A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002651A1 (cg-RX-API-DMAC7.html)
DK (1) DK3952880T3 (cg-RX-API-DMAC7.html)
ES (1) ES3061998T3 (cg-RX-API-DMAC7.html)
FI (1) FI3952880T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251668T1 (cg-RX-API-DMAC7.html)
IL (1) IL287145A (cg-RX-API-DMAC7.html)
LT (1) LT3952880T (cg-RX-API-DMAC7.html)
MA (1) MA55608A (cg-RX-API-DMAC7.html)
MX (1) MX428518B (cg-RX-API-DMAC7.html)
PL (1) PL3952880T3 (cg-RX-API-DMAC7.html)
PT (1) PT3952880T (cg-RX-API-DMAC7.html)
RS (1) RS67593B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111232RA (cg-RX-API-DMAC7.html)
SI (1) SI3952880T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600013T1 (cg-RX-API-DMAC7.html)
TW (1) TWI853014B (cg-RX-API-DMAC7.html)
WO (1) WO2020210418A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107668B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
AU2020369497C1 (en) * 2019-10-21 2026-05-07 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
IL292375A (en) 2019-10-21 2022-06-01 Celgene Corp Solid forms include (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)metyl)benzyl)amino)isoindoline-1 3- Discussion and salts from them, and preparations that include the same and their use
AU2020372333B2 (en) * 2019-10-21 2026-08-06 Celgene Corporation Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
SMT202600194T1 (it) * 2019-10-21 2026-05-12 Celgene Corp Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica
HRP20231487T1 (hr) 2019-10-21 2024-03-01 Celgene Corporation Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona
CN114885602A (zh) * 2019-10-21 2022-08-09 新基公司 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮的药物组合物及其使用方法
IL307257A (en) * 2021-03-29 2023-11-01 Juno Therapeutics Inc A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
US20240207281A1 (en) * 2021-04-21 2024-06-27 Celgene Corporation Methods of treating b-cell lymphoma using combination therapy
CN117241802A (zh) * 2021-04-21 2023-12-15 新基公司 使用2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮治疗非霍奇金淋巴瘤的方法
AU2022300184A1 (en) 2021-06-21 2023-11-16 Celgene Corporation Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione
WO2026099206A1 (en) 2024-11-05 2026-05-15 Celgene Corporation Therapy for the treatment of non-hodgkin lymphoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430669C (en) 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
US8648096B2 (en) * 2006-09-15 2014-02-11 Celgene Corporation N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
EP3351240B1 (en) 2009-05-19 2019-04-10 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
SG183257A1 (en) * 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012177678A2 (en) * 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
UA116544C2 (uk) * 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
US20150297579A1 (en) 2012-11-05 2015-10-22 Celgene Corporation Treatment of cancer with pomalidomide in a renally impaired subject
EP2981262A1 (en) * 2013-04-02 2016-02-10 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
NZ731789A (en) * 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
CN118344338A (zh) * 2018-04-23 2024-07-16 细胞基因公司 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途

Also Published As

Publication number Publication date
RS67593B1 (sr) 2026-01-30
EP3952880A1 (en) 2022-02-16
IL287145A (en) 2021-12-01
SMT202600013T1 (it) 2026-03-09
US11390617B2 (en) 2022-07-19
PL3952880T3 (pl) 2026-05-18
MX428518B (es) 2025-11-13
BR112021020372A2 (pt) 2021-12-07
JP2022527398A (ja) 2022-06-01
US20200325129A1 (en) 2020-10-15
AU2020270917A1 (en) 2021-11-04
TWI853014B (zh) 2024-08-21
DK3952880T3 (da) 2026-01-26
WO2020210418A1 (en) 2020-10-15
EP3952880B1 (en) 2025-12-10
US20240400548A1 (en) 2024-12-05
ES3061998T3 (en) 2026-04-08
US20220324855A1 (en) 2022-10-13
KR20210151895A (ko) 2021-12-14
ZA202107668B (en) 2025-01-29
MX2021012507A (es) 2022-01-24
LT3952880T (lt) 2026-01-26
MA55608A (fr) 2022-02-16
US12103923B2 (en) 2024-10-01
SI3952880T1 (sl) 2026-02-27
JP7562557B2 (ja) 2024-10-07
FI3952880T3 (fi) 2026-02-05
AR119715A1 (es) 2022-01-05
CA3132538A1 (en) 2020-10-15
AU2020270917B2 (en) 2025-08-28
TW202103705A (zh) 2021-02-01
KR102944213B1 (ko) 2026-03-26
CN114144182A (zh) 2022-03-04
CL2021002651A1 (es) 2022-04-29
SG11202111232RA (en) 2021-11-29
PT3952880T (pt) 2026-02-17
CN114144182B (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
SI3952880T1 (sl) 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-dion za uporabo pri zdravljenju ne-hodgkinovega limfoma
CO2021005884A2 (es) Moduladores de la alfa-1 antitripsina
ES3066029T3 (en) 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione for use in treating chronic lymphocytic leukemia
PL3611963T3 (pl) Sposób i urządzenie do przełączania komórek oraz urządzenie użytkownika
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
EP3644999A4 (en) COMPOSITIONS AND METHOD OF USING 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDINE-3-YL) -1-OXOISOINDOLINE-5-YL) METHYL) -2,2-DIFLUOACETAMIDE
IL292258A (en) Pharmaceutical preparations comprising (s)-2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 3, discussion and methods of using them
EP3572050A4 (en) EXCREMENTAL TREATMENT FOR USE IN COLOSTOMIES
IL292266A (en) Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione
JOP20210143A1 (ar) تركيبات وطرق لعلاج ومنع التصلب الجانبي الضموري
EP3912320A4 (en) METHODS AND DEVICES FOR USER DEVICE GROUPING
ZA202006705B (en) Siloxanes for treating textils and for use in cleaning and care formulations
IL284509A (en) Compounds and methods of use of 2-(4-chlorophenyl)-N-((2-(26-deoxypyricin-3-yl)-1-(oxoisoindolin-5-yl)meranyl)-2,2-difluoroacetamide
DK3908582T3 (da) Faste former, som omfatter (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorbenzonitril og salte deraf, og sammensætninger, som omfatter disse, og fremgangsmåder til anvendelse deraf
DK3801515T3 (da) 5 [[4 [2 [5 (1 hydroxyethyl)pyridin 2 yl]ethoxy]phenyl]methyl] 1,3 thiazolidin 2,4 dion og dets salte til anvendelse i behandlingen af mitokondriesygdomme
UA101961C2 (xx) Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида
WO2021080931A8 (en) Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
DK1771415T3 (da) 2-(1H-indolylsulfanyl)-arylaminderivater til anvendelse i behandlingen af affektive sygdomme, smerte, ADHD og stressinkontinens
DK1603584T3 (da) Aplidine til behandling af multipelt myelom
HK40066611A (en) 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione for use in the treatment of non-hodgkin lymphoma
HK40108837A (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3yl)-4-(2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
MX2023012294A (es) Metodos de tratamiento del linfoma no hodgkin mediante el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il) metil)benzil)amino)isoindolin-1,3-diona.
IL307942A (en) Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline -1, 3-dione
HK40079627A (en) Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same
HK40108967A (en) Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione